Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01079091
Other study ID # CS001
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 2010
Est. completion date October 2013

Study information

Verified date July 2019
Source Hepa Wash GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with compensated chronic liver disease who have an episode of acute deterioration of liver function (acute-on-chronic liver failure) are known to have up to 90% mortality rate. Hepa Wash(R) is a newly developed liver and renal support system that is based on the use of recycled albumin dialysate. The new system has shown a high detoxification capacity in in-vitro and preclinical studies. The aim of the study is to evaluate the safety and efficacy of the Hepa Wash system in patients with acute-on-chronic liver failure in the intensive care unit.


Recruitment information / eligibility

Status Terminated
Enrollment 14
Est. completion date October 2013
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patients with documented clinical or histological evidence of cirrhosis AND

2. Acute decompensation in previously stable cirrhotic liver disease AND

3. Bilirubin = 2 mg/dl AND

4. SOFA = 9 calculated after 12 hours of optimal medical therapy AND

5. Patient is in the intensive care unit AND

6. Informed consent of the patient or the legal representative AND

7. Patients are 18y or older AND

8. Enrollment of patients within 96 hours of fulfilling inclusion criteria (1-5)

Exclusion Criteria:

1. Untreatable extrahepatic cholestasis

2. Patient has a survival prognosis of less than 6 weeks because of a chronic disease (e.g. metastasizing cancer) and before the acute event which lead to the ICU admission.

3. PaO2/FIO2 = 100 mmHg (respiratory SOFA-score of 4)

4. Patients who receive a vasopressor support of Dopamine >15 µg/kg/min or epinephrine >0.1 µg/kg/min or norepinephrine >0.1 µg/kg/min (cardiovascular SOFA-score of 4)

5. Patients with creatinine =5 mg/dl or urine output <200 ml/day (renal SOFA-score of 4)

6. Patients on kidney dialysis

7. Patient with MELD-score of 40

8. Mean arterial pressure = 50 mmHg despite conventional medical treatment

9. Patient testament excludes the use of life-prolonging measures

10. Post-operative patients whose liver failure is related to liver surgery

11. Uncontrolled seizures

12. Active or uncontrolled bleeding

13. Weight = 120 kg

14. Pregnancy

15. Patient diagnosed with Creutzfeldt-Jakob disease

16. Participation in another clinical study

Study Design


Intervention

Device:
ADVOS (Hepa Wash)
Intervention frequency: 1-10 treatments (decision of the investigator) Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)
Procedure:
Standard Medical Therapy
Standard of care treatment

Locations

Country Name City State
Germany II Medizinische Klinik, Klinikum rechts der Isar Munich Bavaria

Sponsors (1)

Lead Sponsor Collaborator
Hepa Wash GmbH

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Huber W, Henschel B, Schmid R, Al-Chalabi A. First clinical experience in 14 patients treated with ADVOS: a study on feasibility, safety and efficacy of a new type of albumin dialysis. BMC Gastroenterol. 2017 Feb 16;17(1):32. doi: 10.1186/s12876-017-0569- — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 30-day mortality rate Mortality 30 days after the first intervention 30 days
Secondary Multiorgan system failure according to Sequential Organ Failure Assessment (SOFA) Score The Sequential Organ Failure Assessment (SOFA) Score analyses the severity of illness according to 6 organ systems (CNS, Liver, Kidney, Hemodynamic, Coagulation, Lung). Each system is given 0 to 4 points for a total of 24 points. A value >2 in each of the systems indicates organ failure. An overall value > 14 indicates 90% probability of in-hospital mortality. 72 hours
Secondary Safety (adverse events and surrogate parameters) Adverse Events during the intervention will be assessed. Additionally, liver parameters (e.g. Bilirubin), Kidney Parameters (e.g. Creatinin, Urea) and blood gas analysis will be performed. 30 days
Secondary Number of days on ventilation Number of days with need of mechanical ventilation after first intervention 30 days
Secondary Number of days without extracorporeal treatment Number of days without the need of extracorporeal renal and/or liver replacement therapy after the first intervention 30 days
Secondary 180d-mortality rate Mortality 180 days after the first intervention 180 days
Secondary 1y-mortality rate Mortality 1 year after the first intervention 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05989958 - The Safety and Tolerability Study of HepaCure in Chinese Subjects With Acute-On-Chronic Liver Failure Phase 1
Recruiting NCT03773887 - Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease N/A
Terminated NCT01937130 - Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF Phase 2
Recruiting NCT01698723 - A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus Phase 2
Active, not recruiting NCT02833064 - Biomarkers in Liver Failure
Completed NCT00764049 - Single Pass Albumin Dialysis in Patients With Cirrhosis Phase 1/Phase 2
Completed NCT01383460 - Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure Phase 3
Recruiting NCT05030571 - The Effects of Double Plasma Molecular Adsorption System in Acute on Chronic Liver Failure Patients N/A
Terminated NCT02857010 - Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure Phase 1